In advanced NSCLC responding to first-line chemo-pembrolizumab (n=401 of 666 randomised), adding niraparib to pembrolizumab maintenance did not improve median PFS versus placebo (5.55 vs 5.55 months; HR 1.00). Grade ≥3 toxicity was mainly haematological.
RCTn = 666
Ramalingam et al. Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L)